Mithra Pharmaceuticals SA Market Outlook
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
Roughly 56% of Mithra Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Mithra Pharmaceuticals SA pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Mithra Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Mithra Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Comfort Level 44
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Mithra Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Mithra Pharmaceuticals SA.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Mithra Pharmaceuticals SA is 'Not Rated'. Macroaxis provides Mithra Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MITPF positions.
Execute Mithra Pharmaceuticals Advice
The Mithra recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Mithra Pharmaceuticals SA. Macroaxis does not own or have any residual interests in Mithra Pharmaceuticals SA or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mithra Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
For the selected time horizon Mithra Pharmaceuticals SA has a Return On Equity of -1.39, Return On Asset of -0.11, Operating Margin of (3.60) %, Current Valuation of 425.3 M, Shares Outstanding of 56.31 M and Shares Owned By Insiders of 32.32 %We provide investment recommendation to complement the last-minute expert consensus on Mithra Pharmaceuticals SA. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Mithra Pharmaceuticals is not overpriced, please verify all Mithra Pharmaceuticals SA fundamentals, including its debt to equity, and the relationship between the net income and earnings per share . Given that Mithra Pharmaceuticals has a shares owned by institutions of 15.87 %, we recommend you to check Mithra Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.
Mithra Pharmaceuticals Trading Alerts and Improvement Suggestions
| Mithra Pharmaceuticals is not yet fully synchronised with the market data | |
| Mithra Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Mithra Pharmaceuticals SA has accumulated 125.24 M in total debt with debt to equity ratio (D/E) of 9.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mithra Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mithra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mithra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mithra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mithra to invest in growth at high rates of return. When we think about Mithra Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 22.67 M. Net Loss for the year was (116.88 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Mithra Pharmaceuticals SA has accumulated about 29.3 M in cash with (74.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 32.0% of Mithra Pharmaceuticals outstanding shares are owned by corporate insiders |
Mithra Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mithra . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Mithra Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Mithra Pharmaceuticals SA? Buying financial instruments such as Mithra Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Mithra Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |